• Cisplatin in Cancer Research: Protocols, Applications & Solu

  2026-07-08

  Cisplatin (CDDP) remains the linchpin for apoptosis and chemoresistance studies, powering reproducible workflows from cell viability assays to in vivo xenograft models. This article translates the latest experimental breakthroughs into actionable protocol enhancements for oncology researchers.

• Antibacterial Use and Resistance in Psychiatric Hospitals: C

  2026-07-08

  This article analyzes the innovative retrospective study on antibacterial drug use and bacterial resistance in a psychiatric hospital during the COVID-19 epidemic. The findings reveal a nuanced relationship between rational antibiotic use—particularly third-generation cephalosporins such as cefodizime—and the development of bacterial resistance, with direct implications for infection management and antimicrobial stewardship in closed healthcare environments.

• Pravastatin Sodium: Unraveling Selectivity, Transport, and A

  2026-07-07

  Explore Pravastatin sodium as a highly selective HMG-CoA reductase inhibitor, with an in-depth analysis of its mechanism, transporter interplay, and unique assay considerations. Discover scientific nuances that set this cornerstone guide apart for advanced cholesterol biosynthesis inhibition research.

• Rapamycin (Sirolimus): Precision mTOR Inhibition for Cell As

  2026-07-07

  Rapamycin (Sirolimus) from APExBIO empowers researchers to dissect mTOR-regulated pathways with nanomolar precision, enabling robust cell proliferation suppression and apoptosis assays. This guide demystifies applied workflows, advanced comparative advantages, and troubleshooting strategies for reliable outcomes in cancer, immunology, and mitochondrial disease models.

• XAV-939 in Cardiac Fibrosis and Atrial Fibrillation Models

  2026-07-06

  Explore how XAV-939, a potent Wnt/β-catenin pathway inhibitor, is enabling next-generation research into cardiac fibrosis and atrial fibrillation. This article uniquely bridges molecular mechanism, translational insight, and assay design for cardiovascular disease models.

• Reelin-SFK Pathway: A Key Factor in Ketamine's Antidepressan

  2026-07-06

  This study uncovers that intact synaptic Reelin signaling, particularly through Apoer2 and Src family kinases, is essential for ketamine's rapid antidepressant effects in mouse models. The findings highlight a mechanistic basis for ketamine nonresponse in treatment-resistant depression, informing future research and experimental design.

• Cisplatin (CDDP): Applied Workflows for Cancer Research Succ

  2026-07-05

  Cisplatin (CDDP) is a gold-standard tool for probing DNA damage and apoptosis in cancer research, with unique protocol demands that shape assay reproducibility and interpretability. This guide details optimized workflows, real-world troubleshooting, and the latest advances in overcoming chemoresistance, translating cutting-edge findings into actionable lab practice.

• (S)-(+)-Ibuprofen: Precision COX Inhibition for Translationa

  2026-07-04

  (S)-(+)-Ibuprofen is a potent COX inhibitor vital for inflammation pathway research and pain mechanism study. This article offers a deep dive into its biochemical selectivity, translational relevance, and the critical environmental considerations shaping its use in advanced laboratory and preclinical workflows.

• LY2228820: ATP-Competitive p38 MAP Kinase Inhibitor for Rese

  2026-07-03

  LY2228820 is a highly selective, ATP-competitive p38 MAP kinase inhibitor with nanomolar potency for p38α and p38β isoforms. Its robust inhibition of MAPK signaling enables precise modulation of inflammatory and oncogenic pathways for anti-inflammatory and cancer research. LY2228820’s solubility, stability, and well-defined mechanism make it a benchmark tool for cellular and in vivo studies.

• miR-24-3p Regulates Cardiac Injury via Sp1/PI3K in Heart Fai

  2026-07-03

  This study elucidates the regulatory axis of miR-24-3p, Sp1, and PI3K in doxorubicin-induced heart failure, revealing miR-24-3p as a direct suppressor of Sp1 that exacerbates cardiac dysfunction. The findings identify the miR-24-3p/Sp1/PI3K axis as a promising molecular target for future heart failure interventions and deepen our mechanistic understanding relevant to both cardiac and transcriptional biology.

• Topotecan and SKF104864: Unlocking Translational Impact in C

  2026-07-02

  This thought-leadership article explores the mechanistic and translational potential of Topotecan (SKF104864), a potent topoisomerase I inhibitor. Integrating biological rationale, experimental evidence, strategic guidance, and competitive context, it provides translational researchers with actionable insights and future-facing recommendations. The article contextualizes Topotecan’s unique features—such as blood-brain barrier penetration and efficacy in pediatric solid tumor models—and differentiates itself by bridging advanced mechanistic discussion with workflow optimization, going beyond standard protocol guides.

• Zoledronic Acid: Reliable Solutions for Cancer and Bone Dise

  2026-07-02

  This in-depth guide addresses real-world workflow challenges in cell viability and apoptosis assays using Zoledronic Acid (SKU A1352) as a reproducible, data-backed research tool. The article provides scenario-driven insights, protocol optimization, and comparative vendor analysis, enabling biomedical scientists to achieve robust results in oncology and osteolytic disease models.

• mRNA Vaccine Targeting P1 Protein Confers Immunity to M. pne

  2026-07-01

  A recent study developed and characterized an mRNA vaccine encoding the C-terminal region of the Mycoplasma pneumoniae P1 protein, demonstrating robust induction of specific antibody and T-cell responses in mice. These findings illuminate a promising avenue for combating both standard and macrolide-resistant strains of M. pneumoniae, with practical considerations for immunoassay methodologies.

• Mubritinib–Albumin Binding: Implications for Cancer Drug Des

  2026-07-01

  This study clarifies how mubritinib, a mitochondrial electron transport chain inhibitor, interacts with human serum albumin (HSA) at a molecular level, revealing moderate-affinity binding and functional protein changes. The findings inform strategies for optimizing bioavailability and pharmacokinetics of anti-proliferative agents, with downstream implications for cancer research.

• KR-12 Human Antimicrobial Peptide: Bench Workflows & Optimiz

  2026-06-30

  Harnessing KR-12 human antimicrobial peptide, researchers can model targeted antimicrobial, anti-inflammatory, and anti-biofilm actions with minimal mammalian toxicity. This guide translates cutting-edge findings into practical protocols, troubleshooting strategies, and advanced applications for infection and inflammation research.

16447 records 1/1097 page Next 12345 下5页 Last page